KEYMAKER-U06 Substudy 06E is an open-label phase 1/2 umbrella platform trial evaluating investigational agents in combination with pembrolizumab (MK-3475) with or without chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal cancer. The objective is to assess the safety and efficacy of these combination regimens in the first-line setting. Eligible participants are adults with unresectable or metastatic disease. The trial is conducted using an open-label platform design.
KEYMAKER-U06 Substudy 06E is a phase 1/2 open-label clinical trial. It evaluates new investigational agents in combination with pembrolizumab, with or without chemotherapy. The study includes patients with advanced esophageal cancer that cannot be removed by surgery or has spread to other parts of the body. The treatment is given as first-line therapy for advanced disease. The aim of the study is to assess the safety and effectiveness of these new treatment combinations.
